MedPath

Development and Validation of a Questionnaire to Measure the Impact of SBS and Its Treatments on Patients' Lives

Conditions
SBS - Short Bowel Syndrome
Registration Number
NCT04150302
Lead Sponsor
Central Hospital, Nancy, France
Brief Summary

Today, patients express a very strong need to take into account the consequences of their disease and its treatments in their therapeutic follow-up. It is therefore essential to better understand the needs, expectations and values of patients with SBS in order to better understand the impact of the disease on their lives, and thus improve the conditions for medical, social, psychological and technical care. The clinical expertise of health professionals and meetings with patient associations demonstrate the major gap between the parameters taken into account by physician to evaluate the evolution of the SBS and the day-to-day experience of the disease perceived by the patient.

The objective of the ARTEMIS-GC study is to develop and validate an instrument to measure the impact of SBS and its treatments on daily life from the perspective of patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
250
Inclusion Criteria
  • Patients with SBS defined by a hail length remaining in post-duodenal < 2 meters
  • Patients with intestinal insufficiency, i.e. chronic malabsorption requiring energetic and/or hydro-electrolytic intravenous support for more than 6 months
  • Patients with a period of at least 6 months after the establishment of the SBS
  • Patients who has already had a return home after the establishment of the SBS for a period of at least 3 months
Exclusion Criteria
  • Patients with intestinal insufficiency but with a cause other than SBS
  • Lack of understanding of the study
  • Not speaking French

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Scale calibration of the new developped questionnaireabout 30 minutes

Calibration measure

Structure of the new developped questionnaireabout 30 minutes

Structure identification

Convergence proprieties of the new developped questionnaireabout 30 minutes

Convergence evaluation

Reproducibility of the new developped questionnaireUp to 8 days

Test of reproducibility

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Beaujon Hospital

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath